LIF Monoclonal Antibody (9824)

* CHF, excl. 8.1% VAT and shipping costs

Product Description

In sandwich ELISAs, no significant cross-reactivity or interference with recombinant human (rh) IL-1 alpha, rhIL-1 beta, rhIL-2, rhIL-3, rhIL-4, rhIL-6, rhIL-7, rhIL-8, rhG-CSF, rhGM-CSF, rhOSM, rhTGF-beta 1, rhTNF-alpha, rhTNF-beta, recombinant mouse (rm) IL-1 beta, rmIL-3, rmIL-4, rmIL-5, rmIL-6, rmIL-7, rmGM-CSF, bovine (b) FGF acidic, bFGF basic, human (h) PDGF, porcine (p) PDGF, hTGF-beta 1, pTGF-beta 1.2, or pTGF-beta 2 is observed. Reconstitute at 0.5 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method. Leukemia inhibitory factor (LIF) is a 20 kDa protein that belongs to the IL-6 receptor family. It binds to a heterodimeric membrane receptor made up of a LIF-specific subunit, gp190 or LIFR, and the subunit gp130, which is shared with the other members of the IL-6 family. LIF expression has been observed in various tissues including thymus, lung, and neuronal tissue. LIF can be up-regulated by pro-inflammatory cytokines such as TNFα and IL-17, and elevated levels of LIF have been found in cases of rheumatoid arthritis, neural injury, systemic inflammation, and tuberculosis. LIF displays diverse biological effects, but is best known for its ability to inhibit the differentiation of embryonic stem cells in mice